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The cloned murine cytolytic T-lymphocyte line TEl-IL and several sublines detect a murine cytomegalovirus
immediate-early (IE) membrane determinant in conjunction with Ld class I major histocompatibility
glycoprotein. The lines retained cytolytic activity, strict antigen specificity, and self-restriction even when
adapted to long-term, antigen-independent growth in the presence of interleukin-2 only (M. J. Reddehase,
H.-J. Buhring, and U. H. Koszinowski, J. Virol. 57:408412). These attributes allowed us to use TEl-IL as a
stable, monospecific probe for tracing the expression of the IE membrane antigen throughout the viral
replication cycle. Presentation of the antigen at the cell membrane proved to be most effective when expression
of IE genes in infected mouse embryo fibroblasts was selectively enhanced by consecutive cycloheximide-
actinomycin D treatment, whereas without enhancement high numbers of TEl-IL cytolytic T lymphocytes were
required to demonstrate the antigen in the IE phase. In the early phase of infection when IE genes were no
longer transcribed, cytolysis was not observed, although IE proteins were detectable in the nuclei of the infected
cells. Without application of inhibitors IE membrane antigen expression was most prominent during the late
phase of infection. Reinitiation of transcription from the genomic region encoding the major IE protein (pp89)
and de novo synthesis of pp89 correlated with this reexpression of the IE membrane antigen.
Members of the herpesvirus family such as herpes simplex
viruses, varicella zoster virus, Epstein-Barr virus, and
cytomegalovirus (CMV) establish latency in the im-
munocompetent host, but can cause fatal disease in cases of
immunosuppression (17). Murine CMV (MCMV) infection
has proven a convenient model to investigate aspects of
herpesvirus latency (2, 6), recurrency (10, 15), pathogenesis
(3, 4, 25, 27), and immunity (20, 22) in the natural host.
The replication cycle of herpesviruses can be divided into
three phases of coordinately regulated expression of genes:
the immediate-early (IE; a) phase, the early (,B) phase, and
the late (y) phase (9, 11, 31). A result not anticipated by
previous studies with other herpesviruses was the finding
that IE genes, the first viral genes transcribed after infection
of permissive cells, not only encode regulatory intracellular
proteins essential for viral replication, but also specify a
membrane antigen which serves as a target structure for
MCMV-specific cytolytic T lymphocytes (CTL) (23, 24). The
predominant IE gene product of MCMV, a trans-activating
89,000-dalton (89K) phosphoprotein (pp89) located mainly in
the nucleus of the infected cell, is encoded by gene iel,
which is controlled by a strong transcriptional enhancer (5,
12, 14). Although MCMV virions are composed of many
different structural polypeptides including six glycoproteins
(13), most CTL sensitized during acute infection of mice
were found to recognize target cells after selective enhance-
ment of IE gene transcription (24). Beyond the IE phase, in
the presence of a multitude of proteins specified by MCMV,
IE membrane antigens cannot be discriminated from other
antigens with a polyclonal CTL population as probe. To
trace the presence of a particular IE membrane antigen
throughout the viral replication cycle, we have now used the
* Corresponding author.
cloned CTL line IEl-IL (Lyt-2.2+, L3T4-, Ld restricted)
that defines the antigenic determinant IE1 (21). Data dem-
onstrate that expression of target antigen is mainly a late-
phase event that correlates with reexpression of the major IE
gene.
As anticipated by previous studies (21, 23, 24), the IE
membrane antigen was detected when the expression of IE
genes was enhanced by infection in the presence of cyclo-
heximide. After a period of selective transcription, cyclo-
heximide was replaced by actinomycin D (ActD) to allow
translation of accumulated IE transcripts and to prevent
transcription of early-phase genes (Fig. 1, column A, closed
circles). This protocol also excluded induction of cellular
antigens by pp89-mediated transcriptional activation. The
antigen was not detectable when the same amount of virus,
inactivated by UV light, was used for mock infection (col-
umn A, squares). This control ensured that the antigen
recognized by clone IE1 was not a virion structural antigen
or a cellular antigen induced by virion protein, by inhibitor
treatment, or by an interaction of both. With another CTL
clone, clone Si, a structural antigen can be detected on this
type of target cell (21).
Consistent with previous observations using polyclonal
CTL (23), lysis was barely detectable during the IE phase
when the expression of IE genes was not enhanced (Fig. 1,
column B). At the multiplicity of infection used thrQughout
this experiment, 2 PFU of MCMV per cell, 80 to 90% of
fibroblasts displayed intranuclear pp89 during all phases as
identified with monoclonal antibody MCMV-6/58/1 [immu-
noglobulin G2b (K)] by indirect immunofluorescence. It
should be noted that the observed low level of IE membrane
antigen expression during the IE phase could not be elevated
by raising the multiplicity of infection (data not shown). In
contrast, lysis was more pronounced, in particular when
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effector/target cell ratios are considered, during the late
phase of infection (column C). This finding showed for the
first time that IE membrane antigen is expressed in an
amount sufficient for CTL effector function under conditions
not influenced by application of inhibitors. Similar to the
synthesis of most -y gene products, the presentation of the
IEl epitope during the late phase could be prevented by
infection in the presence of the DNA synthesis inhibitor
phosphonoacetic acid (PAA; column D), while presentation
of the same epitope after selective enhanced expression of
IE genes was not affected by PAA (column A, open circles).
These results demonstrated that the IE membrane antigen
was absent during the early phase (column D) and implied
that synthesis of the late-phase IE membrane antigen also
dated from the late phase.
Since the IE membrane antigen is composed of the viral
IE1 determinant and the cellular Ld glycoprotein encoded by
the major histocompatibility complex, absence or presence
of the compound antigen could reflect the temporal expres-
sion of either component. The expression of Ld antigen
during the early and late phases of infection was therefore
analyzed with an Ld_specific cloned CTL line referred to as
B6aLd (Table 1). This line was derived by cloning from the
polyclonal population of C57BL/6 anti-BALB/c CTL already
used in a previous report (21). Specificity mapping for line
B6aLd is demonstrated in Table 1, experiment 1. The data
shown in Table 1, experiment 2, revealed no significant
difference in the expression of Ld between noninfected
fibroblasts and fibroblasts during the early or late phase of
MCMV replication, but again, the IE membrane antigen was
detected during the late phase. Superinfection by virions
released during the late phase must be discussed as one
possible explanation for this observation. Three findings,
however, are not consistent with that interpretation. First,
as already mentioned above, raising the multiplicity of
infection under IE conditions did not result in more pro-
nounced lysis of target cells by clone IEL. It is therefore not
likely that superinfection at a later stage would cause en-
hanced expression of the IE membrane antigen. Second,
production and release of virions in the late phase did not
enhance the susceptibility of target cells to lysis by CTL
clone S1 (not shown), although this clone has been shown
previously to detect, in a dose-dependent manner, a viral
structural antigen integrated into the target cell membrane
from without during the penetration step of infection (21).
Third, the IE membrane antigen was found to be expressed
in the late phase also when significant release of infectious
virus was prevented by halting late-phase transcription with
ActD (Table 1). Enhanced expression of the IE membrane
antigen during the late phase can therefore not be explained
by superinfection.
Altogether, the viral determinant TEl was found to be
reexpressed in the late phase and thus predicted reexpres-
sion of a viral IE gene during the late phase, presumably due
to transcription of the gene from an increased number of
templates.
That was indeed the case, as shown by a nuclear run-on
transcription assay (8) (Fig. 2A). RNA synthesized in nuclei
isolated at different times during the viral replication cycle
was hybridized to iel sequences contained in plasmid
pIE110 (14) as the specific probe and to vector pSP62 DNA
(16) for control. Transcription from the genomic region
represented by pIE110 was detectable during the IE phase
(a; 1 h postinfection [p.i.]), ceased during the early phase (,B;
8 h p.i.), and was initiated again in the beginning late phase
(Y16; 16 h p.i.) (11), increasing with time (Y24; 24 h p.i.).
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FIG. 1. Expression of the IEl epitope during the replication
cycle of MCMV. Line IEl-IL of CTL clone IE1 was used to detect
the IEl epitope. Selection and properties of this line have been
described before (21). Selective, enhanced synthesis of IE proteins
in target cells (column A, closed circles) was achieved by infection
of tertiary mouse embryo fibroblasts [BALB/c, (KDL)d] with
MCMV (ATCC VR-194, Smith strain) in the presence of cyclohex-
imide (CH; 50 ,ug/ml) that was replaced after 3 h by Act.D (5 ,ug/ml).
In the case of nonenhanced expression of a genes, Act.D was added
1.5 h p.i. (column B). PAA (250 ,ug/ml) was added before infection
(columns A and D, open circles). For mock infection (column A,
squares), MCMV was inactivated with UV light as described
previously (24). Fibroblasts in the late phase of infection were
assayed 24 h p.i. (column C). For each of the indicated ef-
fector/target cell ratios (1,000 51Cr-labeled target cells), specific lysis
was determined in six replicates in a standard 3-h 51Cr-release assay.
Mean values are normalized to the maximum specific lysis observed
(46% at effector/target cell ratio of 10; column A, closed circle). The
dashed lines represent the upper 95% confidence limit of spontane-
ous lysis.
Transcription unrelated to gene iel from a putative late gene
on the opposite strand might have contributed to the signal in
the run-on assay, but reexpression of gene iel was proved by
Northern blot hybridization revealing the 2.75-kilobase RNA
that specifies pp89 (not shown), and immunoprecipitation of
proteins biosynthetically labeled during the late phase (20 to
24 h p.i.) positively identified pp89 as one of the proteins
synthesized in the late phase (Fig. 2B). Several late-phase
polypeptides could be precipitated with immune serum,
including an 89K protein (lane-a) that was identified as pp89
by precipitation with specific monoclonal antibody (lane b).
The synthesis of late-phase proteins, including late synthe-
sized pp89, was inhibited (lanes c and d) when infection was
performed in the presence of PAA. This result confirmed
that viral DNA synthesis is required for reexpression of
pp89.
In conclusion, although intranuclear pp89 could be de-
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TABLE 1. Expression of class I major histocompatibility complex (MHC) Ld antigen during early and late phases of MCMV infection
o% Specific lysis at E/T ratios of 10, 5, and 1 by
Target cells Class I MHCd MCMV replication clone:glycoproteins phase d
BMaxLd IE1.18-IL
Expt ia
KD2SV (KDL)d 59, 46, 21
KHTGSV Kd 3, 0, 2
Ltk- 1, 1, 0
Ltk-H-2Ld Ld 43, 33, 22
Expt 2b
MEF (-) (KDL)d None 48, 31, 18 2, 2, 1
Early-MEF (2) (KDL)d a + d 55, 39, 23 0, 3, 0
Late-MEF (2) (KDL)d a + 13 + Y 50, 36, 17 11, 8, 4
a Lytic activity of the cloned CTL line B6aLd was determined in six replicates for the indicated effector/target cell (E/T) ratios. The mean value of specific lysis
is given without normalization. Simian virus 40-transformed cell lines KD2SV (B1O.D2 origin) and KHTGSV (B1O.HTG origin), as well as Ltk- cells (C3H/An
origin) or Ltk- cells transfected with the H-2Ld gene (Ltk- H-2Ld; 19), served as target cells in a 3-h 51Cr-release assay.
b BALB/c mouse embryo fibroblasts (MEF) served as target cells either noninfected (-) or infected with MCMV at a multiplicity of 2 PFU per cell. In early-
MEF, PAA (250 ,ug/ml) was added before infection. In late-MEF, Act.D (5 p.g/ml) was added 20 h p.i. IE1.18-IL is a subline of IEl-IL.
pIE 110
pSP 62
as 1l y16 Y24 Ama
-.'. v E<w 4
y-phase proteins
-PAA +PAA
a b c d
200K-
140K -
129K -
89K- qg_
tected with monoclonal antibody during all phases, the IE
membrane antigen was not detectable during the early phase
when gene iel was not transcribed, but was detectable in the
late phase when expression of gene iel was reinitiated.
These conditions have two important implications. First,
presentation of IE target antigen is not correlated with
intranuclear presence of the major IE protein, but rather
with its synthesis, and second, infected fibroblasts are sus-
ceptible to lysis by IE-specific CTL mainly during the late
phase of viral,replication.
Recent findings in vital immunology converge to the
conclusion that viral genes which do not code for classical
cell membrane glycoproteins, but for proteins located mainly
in the nucleus of the infected cell, specify immunodominant
determinants recognized by CTL in conjunction with class I
major histocompatibility glycoprotein. Prominent examples
are the nonstructural large-T antigen of the papovavirus
simian virus 40 (18, 28) and the internal virion nucleoprotein
of the myxovirus influenza A (29, 30, 33). These viruses
encode only a low number of proteins. Considering the high
coding capacity ofMCMV (7), it is remarkable that the same
prin-
ciple appears to rule the CTL response to this virus (21, 23,
24). Analysis of the organization of the MCMV IE region has
revealed minor IE gene products besides the by far most
abundantly synthesized pp89 encoded by gene iel (G. M.
Keil, A. Ebeling-Keil, and U. H. Koszinowski, submitted
for publication). Whether a candidate for cell membrane
50K-
46K-
FIG. 2. Identification of a gene products during the late phase of
MCMV replication. (A) Transcription of IE gene iel in nuclei
isolated from 10' infected mouse embryo fibroblasts (multiplicity of
50 PFU per cell) during different phases of MCMV replication (a, 1
h p.i.; P, 8 h p.i.; Y16, 16 h p.i.; y24, 24 h p.i.) was monitored by a
nuclear run-on transcription assay performed essentially as de-
scribed previously (8). Run-on transcripts labeled with [a-32P]UTP
for 30 min were hybridized at 72°C for 48 h with 1 pmol of iel gene
plasmid pIE110 DNA (14) or vector pSP62 DNA (16) bound to
nitrocellulose filters. Addition of a-amanitin (1 p.M) blocked
transcription in all phases, shown for late phase (Y24) nuclei (slot
Ama). Consistent with the fact that MCMV does not induce shutoff
of host transcription, incorporation of radioactivity was equal in all
preparations. In addition, the hybridization signal to P-actirl cDNA(kindly provided by B. M. Paterson, National Institutes of Health,
Bethesda, Md.) remained invariant (not shown). (B) Polypeptides,
labeled biosynthetically in 2 x 106 infected mouse embryo fibroblasts
(multiplicity of 50 PFU per cell) with 1.5 mCi of [35S]methionine per
ml during the late phase (20 to 24 h p.i.), were analyzed by immuno-
precipitation (12) with immune serum (lanes a and c) or IEpp89-
specific monoclonal antibody MCMV-6/20/1 [immunoglobulin G2a
(K)] (12) (lanes b and d). PAA (250 ,ug/ml) was added before infection
(lanes c and d).
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expression is among these minor proteins, or whether the
intranuclear pp89 itself is degraded to antigenic peptides
presented at the cell membrane in a mode similar to that
postulated for influenza A nucleoprotein (29, 30), remains to
be investigated.
While the presence of a regulatory IE protein during the y
phase has been reported for herpes simplex virus type 1 (32),
the coincidence of a gene reexpression and presentation of
an IE target antigen for CTL during the y phase of MCMV
infection is a new finding relevant to immune surveillance.
In a previous communication we postulated sites of pref-
erential IE gene expression to explain the high frequency of
IE-specific CTL (24). Since fibroblasts display only class I
major histocompatibility antigen, efficient in vivo induction
of an IE-specific CTL response also predicts cells that
present IE membrane antigen in association with class II
major histocompatibility antigen. Recent investigations have
identified monocytes and lymphocytes as sites where, in
fact, replication of human CMV is restricted to expression of
IE genes (26). Whether these cells also present an IE antigen
at the cell membrane and whether CTL that recognize
human CMV-infected cells at early times in the replication
cycle (1) are directed specifically to an IE membrane antigen
await further analysis.
The regulatory function of IE proteins implies that tran-
scription of (x genes is a decisive step in virus reactivation
from latency. IE antigen-specific memory CTL (23) are
candidates to counteract recurrency in its initial phase. At
first glance, the finding that CTL effector function appears to
be executed mainly during the late phase seems to be
inconsistent with that predicted role of CTL. Two argu-
ments, however, have to be considered. First, antigen pre-
sentation in permissive fibroblasts infected in vitro is not
necessarily representative of other cell types and antigen
presentation in vivo. Second, when taking into account the
dynamics of the protracted replication cycle of CMVs, the
kinetics of IE membrane antigen expression observed in
fibroblasts could indeed promote the function of IE-specific
CTL. If we speculate that a low level of antigen expression
is sufficient for in vivo sensitization of memory CTL already
during the IE phase, the generated effector CTL could
deliver the lethal hit during the late phase to the same cells
by which they have been triggered.
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